RPRX
$32.6
Revenue | $594Mn |
Net Profits | $208Mn |
Net Profit Margins | 35.02% |
Royalty Pharma Plc’s revenue fell -0.34% since last year same period to $594Mn in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated 5.19% jump in its revenue since last 3-months.
Royalty Pharma Plc’s net profit fell -57.92% since last year same period to $208Mn in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated -61.76% fall in its net profits since last 3-months.
Royalty Pharma Plc’s net profit margin fell -57.78% since last year same period to 35.02% in the Q4 2024. On a quarterly growth basis, Royalty Pharma Plc has generated -63.65% fall in its net profit margins since last 3-months.
EPS Estimate Current Quarter | 1.05 |
EPS Estimate Current Year | 1.05 |
Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.05 - a 13.33% jump from last quarter’s estimates.
Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.05.
Earning Per Share (EPS) | 1.15 |
Dividend Per Share (DPS) | 0.21 |
Royalty Pharma Plc’s earning per share (EPS) jumped 0.1% since last year same period to 1.15 in the Q4 2024. This indicates that the Royalty Pharma Plc has generated 0.1% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Royalty Pharma Plc declared 0.21 dividend per share during the earnings announcement for Q4 2024.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-02-12 | 1.05 | 1.15 | 9.21% |
2024-11-06 | 0.93 | 1.01 | 8.6% |
2024-05-09 | 0.98 | 0.98 | 0% |
2024-08-08 | 0.97 | 0.96 | -1.03% |